Interaction Color Code
Clinical Bottom Line
Adjust dosing to avoid reduced levels of raltegravir
Drug 1
Drug 1 dose
400 mg BID
Drug 1 effect
When given with rifapentine once weekly for 3 weeks raltegravir AUC increased 79%, Cmax increased 89% and Cmin decreased 12%. When given with rifapentine for 10 daily doses, Cmin decreased 41%
Drug 2
Drug 2 dose
900 mg once weekly for 3 weeks or 600 mg once daily for 10 scheduled doses (days 1, 4?8 and 11?14)
Clinical Effects
Potential for increased raltegravir adverse effects if given with rifapentine once weekly; potential for loss of antiviral response if rifapentine coadministered daily
Management
When coadministering with once weekly rifapentine use raltegravir 400 mg BID. Do not coadminister raltegravir with once daily rifapentine.
Import ID
286
